Robert B M Landewé

InstitutionAmsterdam Rheumatology Center
AddressThe
Netherlands
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 16 Covid-19 publications, with a maximum of 2 publications in July 2020 and August 2020 and December 2020 and February 2021
    All Publications
    Bar chart showing 102 publications over 19 distinct years, with a maximum of 12 publications in 2017
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Landewé RB, Ramiro S, Mostard RLM. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein et al. Ann Rheum Dis. 2021 Jun 23. PMID: 34162596.
      Citations:    Fields:    
    2. Janssen MTHF, Ramiro S, Landewé RBM, Magro-Checa C, Mostard RLM. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. Ann Rheum Dis. 2021 10; 80(10):1362-1363. PMID: 33958327.
      Citations: 1     Fields:    Translation:Humans
    3. Ramiro S, Mostard RLM, Landewé RBM. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al. Ann Rheum Dis. 2021 Apr 26. PMID: 33903095.
      Citations:    Fields:    
    4. Landewé RBM, Ramiro S, Mostard RLM. COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. RMD Open. 2021 03; 7(1). PMID: 33790049.
      Citations: 3     Translation:Humans
    5. Ramiro S, Mostard RLM, Landewé RBM. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis et al. Ann Rheum Dis. 2021 Feb 16. PMID: 33593737.
      Citations:    Fields:    
    6. Ramiro S, Mostard RLM, Landewé RBM. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. Ann Rheum Dis. 2021 Feb 15. PMID: 33589439.
      Citations:    Fields:    
    7. Ramiro S, Mostard R, Landewé RB. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda et al. Ann Rheum Dis. 2020 Dec 14. PMID: 33318060.
      Citations:    Fields:    
    8. Martens RJH, van Adrichem AJ, Mattheij NJA, Brouwer CG, van Twist DJL, Broerse JJCR, Magro-Checa C, van Dongen CMP, Mostard RLM, Ramiro S, Landewé RBM, Leers MPG. Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. Clin Chem Lab Med. 2021 03 26; 59(4):783-793. PMID: 33554540.
      Citations: 4     Fields:    Translation:HumansCells
    9. Ramiro S, Landewé RBM, Mostard R. Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev et al. Ann Rheum Dis. 2020 Oct 30. PMID: 33127663.
      Citations:    Fields:    
    10. Ramiro S, Mostard R, Landewé RB. Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al. Ann Rheum Dis. 2020 Aug 19. PMID: 32816700.
      Citations:    Fields:    
    11. Kroon FPB, Mikuls TR, Landewé RB. COVID-19 and how evidence of a new disease evolves. Ann Rheum Dis. 2020 Aug 12. PMID: 32796046.
      Citations:    Fields:    
    12. Landewé RBM, Schulze-Koops H. Response to: 'Should patients starting biologics be screened for COVID-19?' by Cardenas-de la Garza et al. Ann Rheum Dis. 2020 Jul 22. PMID: 32699038.
      Citations:    Fields:    
    13. Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, Gronenschild M, de Kruif MD, van Haren EHJ, van Kraaij T, Leers MPG, Peeters R, Wong DR, Landewé RBM. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020 09; 79(9):1143-1151. PMID: 32719045.
      Citations: 69     Fields:    Translation:HumansCellsPHPublic Health
    14. Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A, Isaacs JD, Mariette X, McInnes I, Mueller-Ladner U, Openshaw P, Smolen JS, Stamm TA, Wiek D, Schulze-Koops H. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020 07; 79(7):851-858. PMID: 32503854.
      Citations: 66     Fields:    Translation:HumansCellsPHPublic Health
    15. van Kraaij TD, Mostard RL, Ramiro S, Magro Checa C, van Dongen CM, van Haren EH, Buijs J, Landewé RB. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. Eur J Case Rep Intern Med. 2020; 7(5):001675. PMID: 32399455.
      Citations: 11     
    Landewé's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (141)
    Explore
    _
    Co-Authors (48)
    Explore
    _
    Similar People (60)
    Explore
    _